BAL PHARMA LTD. - Impact Of COVID-19 Pandemic

Download	< Back
26 May 2020
Ref : SEBI circular # SEBI/HO/CFD/CMD1/CIR/P/2020/84 Dated 20/05/2020.<BR> <BR> The impact of the outbreak of COVID-19 pandemic has exposed the dependency of the Indian pharma industry on China, for its API procurement. Production schedules of the Company was also affected during March 2020 due to the short supply of raw materials and impaired logistics. <BR> <BR> Other then marginal delays in receipt of the payments from the suppliers, the Company has not faced any major cash flow issues during the lock down period. All the manufacturing units of the Company are functioning during the lock down, as pharmaceuticals are in the category of essential commodities and the Company has taken all precautionary measures as prescribed by the government to ensure safety of its employees. <BR> <BR> First quarter of the current financial year is very promising as most of the world markets are gradually opening up and we expect normalcy to return very shortly. <BR>
View all announcements for BAL PHARMA LTD.	Source: BSE India

Stocks	Mutual Funds		Investment tracking
A-Z Gainers - Daily \| Weekly \| Monthly Losers - Daily \| Weekly \| Monthly Group-wise listing IPO \| Top IPOs Recent IPOs \| IPO News Similar Price band Most traded - By volumes Top 100 - By market capitalisation Latest Company Results Management Speaks Market News	Top 25 schemes High-risk, High-returns Medium-risk, Medium-returns Low-risk, Low-returns Gilt Funds Funds of Funds Special Funds Liquid Funds Dynamic Asset Allocation NFOs MF Selector	Equity - ELSS Equity - Index Funds Equity - Sector Funds Equity - Balance Fund Equity - Diversified Fund MF News Budget 2024	My Portfolio My Watch List If You Had Invested... Global Indicators Forex Converter Market Indices Sectoral Indices World Indices Market Astrology Advertise with us